Translating preclinical insights into clinical success: bench to bedside ADCs

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Translating preclinical insights into clinical success: bench to bedside ADCs

Preclinical data can be compelling, but the path from bench to bedside in ADC development is rarely straightforward. This live podcast examines the factors that drive, and those that disrupt, successful translation across the full ADC development arc, from early discovery and preclinical modeling through IND-enabling studies to first-in-human trials and early clinical evaluation.

We will draw on direct experience of ADC programs to explore where preclinical assumptions hold, where they break down, and how those lessons are informing more robust translational strategies.

Attend this session to:

Discover where translational gaps most commonly emerge in ADC programs
Gain expert perspectives on translating preclinical pharmacology and safety data into clinical trial design
Explore the key decision points between preclinical and clinical development that determine whether an ADC program advances or stalls
Learn how early clinical readouts refine preclinical strategies and de-risk later-stage ADC development

Valerie Vanhooren, PhD

Co-founder and Chief Executive Officer at Ona Therapeutics

Since 2019, Valerie has guided the growth and development of Ona Therapeutics pipeline of first-in-class ADCs and antibodies and secured over €35 million from a syndicate of international investors and non-dilutive grants. She has extensive experience in the discovery and development of antibodies and protein conjugates for oncology. Prior to Ona, she held leading R&D roles at SpliceBio and Ablynx (acquired by Sanofi), where she led drug development collaborative partnerships with multiple internationally operating pharmaceutical entities, including Merck and AbbVie. Valerie holds a PhD in Biotechnology from the University of Ghent, Belgium.